| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 10/27/2004 | EP1470821A2 Cell therapy method for the treatment of tumours |
| 10/27/2004 | EP1470240A2 Methods and compositions for treating cardiovascular disease using 1682, 6169, 6193, 7771, 14395, 29002, 33216, 43726, 69292, 21656, 32427, 2402, 7747,1720, 9151, 60491, 1371, 7077, 33207, 1419, 18036, 16105, 38650, 14245, 58848, 1870, 25856, 32394, 3484, 345, 9252, 9135, 10532, 18610, 8165,2 |
| 10/27/2004 | EP1470239A2 Psoriasin expression by breast epithelial cells |
| 10/27/2004 | EP1470237A2 Multifunctional monoclonal antibodies directed to peptidoglycan of gram-positive bacteria |
| 10/27/2004 | EP1470223A2 Homologous 28-kilodalton immunodominant protein genes of ehrlichia canis and uses thereof |
| 10/27/2004 | EP1470218A2 Corona-virus-like particles comprising functionally deleted genomes |
| 10/27/2004 | EP1470217A1 Generation and use of dendritic cells |
| 10/27/2004 | EP1470161A1 Bispecific antibody dna constructs for intramuscular administration |
| 10/27/2004 | EP1470160A2 Immune globulin formulations for the treatment and prevention of an orthopoxvirus infection |
| 10/27/2004 | EP1470159A2 Antibody to latent membrane proteins and uses thereof |
| 10/27/2004 | EP1470154A1 Peptides and nucleic acids of the cathelicidin family, derived from fish, and uses thereof |
| 10/27/2004 | EP1470146A2 Antibodies against the muc18 antigen |
| 10/27/2004 | EP1469882A2 Treatment of ms with goat serum |
| 10/27/2004 | EP1469881A2 Vaccine adjuvant based on a cd40 ligand |
| 10/27/2004 | EP1469880A2 Method for reducing morbidity and mortality in critically ill patients |
| 10/27/2004 | EP1469878A2 Fgfr agonists |
| 10/27/2004 | EP1469877A2 B-cell lymphoma specific antigen for use in diagnosis and treatment of b-cell malignancies |
| 10/27/2004 | EP1469869A2 Peptide useful in immunomodulation |
| 10/27/2004 | EP1469849A1 Treating stress response with chemokine receptor ccr5 modulators |
| 10/27/2004 | EP1387701B1 Immunoconjugates made of egg-yolk antibodies (igy), production and use thereof in diagnoses and therapy |
| 10/27/2004 | EP1169057B1 Anti-hiv 1 vaccine comprising the entire or part of the tat hiv-1 protein |
| 10/27/2004 | EP1079860B1 Nicotine immunogen |
| 10/27/2004 | EP0897427B1 Polysaccharide precipitation process |
| 10/27/2004 | EP0845270B1 Functional fragment antigen of tetanus toxin and tetanus vaccine |
| 10/27/2004 | EP0807125B1 Monoclonal antibodies anti-cd6 for the treatment and diagnosis of psoriasis |
| 10/27/2004 | EP0746338B1 Vaccines containing paucilamellar lipid vesicles as immunological adjuvants |
| 10/27/2004 | EP0721015B1 Monoclonal antibody that induces apoptosis |
| 10/27/2004 | EP0717108B1 Recombinant prrs proteins, diagnostic kits and vaccines containing said recombinant proteins |
| 10/27/2004 | CN1541266A FCE fusion proteins for treatment of allergy and asthma |
| 10/27/2004 | CN1541226A Antibodes specific for CD44V6 |
| 10/27/2004 | CN1541225A Humanized antibodies that recognize beta amyloid peptide |
| 10/27/2004 | CN1541224A Antagonistic anti-hTNFSF13b Human antibodies |
| 10/27/2004 | CN1541222A Antibodies to non-functional P 2 Chi 7 receptor diagnosis and treatment of cancers and other conditions |
| 10/27/2004 | CN1541126A Microprojection array having beneficial agent contg coating |
| 10/27/2004 | CN1541111A Mutant forms of cholera holotoxin as adjuvant |
| 10/27/2004 | CN1541110A Methods for sterilizing prepns of monoclonal immunoglobulins |
| 10/27/2004 | CN1541109A Inhibitors of HER3 activity |
| 10/27/2004 | CN1541108A Vaccine compsn. comprising at least two valences, one enhanced with adjuvant and not other |
| 10/27/2004 | CN1541095A 抑制炎症的化合物 The compounds inhibit inflammation |
| 10/27/2004 | CN1539970A Heterophil neutral leucocyte factor alpha |
| 10/27/2004 | CN1539849A Polypeptides encoded by haman lipase-like gene and compsns, and metods of utilizing same |
| 10/27/2004 | CN1539505A Stable isotonic lyophilized protein formulation |
| 10/27/2004 | CN1539504A Bacterin of tabling gene of E type hepatitis virus |
| 10/27/2004 | CN1539503A Quick acting bacterin for SARS |
| 10/27/2004 | CN1539502A Unique idiocratic innunization method for against cancer |
| 10/27/2004 | CN1172718C Dendritic cell stimulatory factor |
| 10/26/2004 | US6809189 Apoptin-associating protein |
| 10/26/2004 | US6809185 Created by heterodimerization of immunoglobulin domains; have two or more antigen binding parts; for diagnosis/treatment of human diseases |
| 10/26/2004 | US6809179 Immunogenic peptides used in immunotherapy of cancers/tumors; immunostimulants |
| 10/26/2004 | US6809175 Cadherin derived growth factor and its use |
| 10/26/2004 | US6808930 Labelling reagent; can be used in diagnosis and therapy of cancer/tumors; detection of penetration of nucleus susceptible to alpha-lactalbumin (mal) |
| 10/26/2004 | US6808902 Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules |
| 10/26/2004 | US6808880 Method for detecting polynucleotides encoding telomerase |
| 10/26/2004 | US6808877 Ligands for FPR class receptors that induce a host immune response to a pathogen or inhibit HIV infection |
| 10/26/2004 | US6808714 Nucleotide sequences for use in the detection of microorganismal infections |
| 10/26/2004 | US6808713 Chlamydia antigens and corresponding DNA fragments and uses thereof |
| 10/26/2004 | US6808712 Imunogenic a beta fragment linked to immunoglobulin carrier to form conjugate; adjuvant comprising antibodies to a beta fragment enhances immune response; alzheimer*s disease treatment |
| 10/26/2004 | US6808711 Immunologically active proteins from Borrelia burgdorferi, nucleic acids which encode them, and their use in test kits and as vaccines |
| 10/26/2004 | US6808710 Contacting cell expressing pd-1 with binding agent; genetic transduction of negative signal |
| 10/26/2004 | CA2263888C Methods and compositions for the detection of cervical cancer |
| 10/26/2004 | CA2177616C Preparation and use of immunoconjugates |
| 10/26/2004 | CA1341461C T helper cell growth factor |
| 10/21/2004 | WO2004090113A2 L53, a lung cancer associated antigen and uses thereof |
| 10/21/2004 | WO2004090095A2 Generation of human regulatory t cells by bacterial toxins for the treatment of inflammatory disorders |
| 10/21/2004 | WO2004089984A1 Antigen recognizing antibody |
| 10/21/2004 | WO2004089983A2 Severe acute respiratory syndrome (sars) causing coronavirus |
| 10/21/2004 | WO2004089980A2 Therapeutic cancer vaccine |
| 10/21/2004 | WO2004089978A2 Use of hcv proteins |
| 10/21/2004 | WO2004089417A1 Drug-enclosing multilayer structure particulate and process for producing the same |
| 10/21/2004 | WO2004089413A1 Nucleotide and cellular vaccine composition |
| 10/21/2004 | WO2004089408A2 Vaccine preparations comprising live or killed attenuated mutant neisseria bacteria |
| 10/21/2004 | WO2004089405A1 Therapeutic composition for autoimmune conditions |
| 10/21/2004 | WO2004089299A2 Pulsatile transdermally administered antigens and adjuvants |
| 10/21/2004 | WO2004089294A2 Compositions, methods and kits relating to her-2 cleavage |
| 10/21/2004 | WO2004078912A3 Chicken rna polymerase i promoter and the use thereof |
| 10/21/2004 | WO2004062567A3 Arterivirus marker vaccine |
| 10/21/2004 | WO2004050691A3 A method for the production of hiv-1 gag virus-like particles |
| 10/21/2004 | WO2004043428A3 Buccal, polar and non-polar spray or capsule containing drugs for treating pain |
| 10/21/2004 | WO2004043405A3 Polysaccharide vaccine for staphylococcal infections |
| 10/21/2004 | WO2004037189A3 Methods for vaccinating against malaria |
| 10/21/2004 | WO2004034971A3 Methods for treating and preventing sepsis using modified c1 inhibitor or fragments thereof |
| 10/21/2004 | WO2004032832A3 Bispecific molecule comprising an anti-cr1 antibody cross-linked to an antigen-binding antibody fragment |
| 10/21/2004 | WO2004009776A3 TREATMENT OF TNFα RELATED DISORDERS |
| 10/21/2004 | WO2004009032A3 Method and composition for treating and preventing hepatitis b infection and symptoms thereof |
| 10/21/2004 | WO2003102219A3 Improved pseudotyped retroviruses |
| 10/21/2004 | WO2003093793A3 Binary or polynary targeting and uses thereof |
| 10/21/2004 | WO2003062375A3 Stabilizing polypeptides which have been exposed to urea |
| 10/21/2004 | WO2003061692A3 Hepatitis b virus surface antigen as a mucosal immunostimulator and the resulting formulations |
| 10/21/2004 | WO2003060081A3 Compositions and methods relating to endometrial specific genes and proteins |
| 10/21/2004 | WO2003027266A3 Whitefly ecdysone receptor nucleic acids, polypeptides, and uses thereof |
| 10/21/2004 | WO2003026490A3 Methods and compositions for prevention, diagnosis, and treatment of cancer using bispecific molecules |
| 10/21/2004 | WO2003025120A3 Clasp membrane proteins |
| 10/21/2004 | WO2003024392A3 Compositions and methods for the diagnosis and treatment of tumor |
| 10/21/2004 | WO2003000014A3 Spherical protein particles and methods of making and using them |
| 10/21/2004 | US20040210038 Il-1 eta DNA and polypeptides |
| 10/21/2004 | US20040210037 Comprises major histocompatibility complex fusion protein for use in treating and/or preventing cancer, infection, allergies and autoimmune diseases |
| 10/21/2004 | US20040209942 treating cancer and apoptosis-associated disorders using cell cycle checkpoint activation modulators; also screening for the modulators |
| 10/21/2004 | US20040209836 activation of antigen-presenting cells; modifying dendritic cells to express an inducible form of a co-stimulatory polypeptide molecule; used to bolster the immune response of an immunocompromised subject, such as an HIV-infected subject |
| 10/21/2004 | US20040209805 such as fibrosis via activin antagonist (fullistatin); kits; gene therapy; treating inflammatory bowel disease and crohn's disease |
| 10/21/2004 | US20040209379 Diagnosis and monitoring of diseases |